Published study records

Study records for ARA-290

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

64 study records.

0 evidence-verified · 44 citation-verified · 20 citation-only

Verified records by research setting

Human research: 7
In vitro: 6
In vivo/preclinical: 31
Review/meta-analysis: 0
Other: 0

Current study records

Study type: In vivo/preclinical · Status: Citation identity verified

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.

European journal of pharmacology · 2025

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.

International dental journal · 2025

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.

CNS neuroscience & therapeutics · 2024

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in Mice.

Neuroscience bulletin · 2024

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways.

Inflammation · 2023

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.

Frontiers in pharmacology · 2022

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.

Frontiers in cardiovascular medicine · 2022

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.

International journal of molecular sciences · 2021

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Multifaceted roles of a bioengineered nanoreactor in repressing radiation-induced lung injury.

Biomaterials · 2021

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand.

Transplantation · 2020

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

Journal of clinical medicine · 2020

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.

Toxicology in vitro : an international journal published in association with BIBRA · 2020

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

ARA-290: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.